[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"poor-ovarian-reserve\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:poor-ovarian-reserve":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100649613","phase-1-drospirenone-primed-ovarian-stimulation-versus-gnrh-antagonist-protocol-in-poor-ovarian-responders-undergoing-freeze-all-ivficsi-100649613",false,"NCT07736261","Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF\u002FICSI","Drospirenone-Primed Ovarian Stimulation (PPOS) Versus Flexible GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing a Freeze-All Strategy: A Pilot Randomized Controlled Trial","PPOS","Inclusion Criteria:\n\n* Spontaneous menstrual cycles (21-35 days)\n* Poor ovarian response per Bologna criteria (≥2 of 3): advanced age ≥40 or risk factor for POR; previous poor response (≤3 oocytes with conventional stimulation); abnormal ovarian reserve (AFC \\\u003C7 or AMH \\\u003C1.1 ng\u002FmL)\n* POSEIDON group recorded at enrollment (1-4) for stratified randomization and pre-specified subgroup description - corrects a known limitation of Bologna-only classification, which pools biologically distinct POR phenotypes\n* Indication for IVF\u002FICSI\n* Willing and able to undergo mandatory freeze-all\u002FFET protocol\n* Signed informed consent, including explicit acknowledgment that fresh transfer is not offered in either study arm\n\nExclusion Criteria:\n\n* Contraindication to ovarian stimulation\n* Known müllerian anomaly\n* Uncontrolled systemic disease\n* 5 prior failed IVF attempts\n* Known contraindication to drospirenone (per product labeling, e.g., renal impairment, adrenal insufficiency, conditions predisposing to hyperkalemia)","FEMALE","20 Years","42 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Participants will:\n\n* Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections\n* Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study)\n* Have a frozen embryo transferred in a later cycle\n* Complete two short questionnaires about their treatment experience - once before starting the injections\u002Fpills, and once after the stimulation phase ends\n* Be followed to determine if the embryo transfer results in a pregnancy",[29,30],"Poor Ovarian Reserve","Infertility (IVF Patients)",[32,33,34,35,36,37],"poor ovarian response","diminished ovarian reserve","Drospirenone","progestin primed ovarian stimulation","GnRH antagonist","Freeze all","NOT_YET_RECRUITING","2026-07-29",{"date":41,"type":42},"2026-07-30","ACTUAL",{"date":44,"type":22},"2026-08",{"date":46,"type":22},"2027-11",{"name":48,"class":49},"Ahmed Saad","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100594522","ovarian-prp-injections-for-improved-embryo-quality-using-embryo-quality-score-100594522","NCT07020546","Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score","Ovarian Platelet-Rich Plasma (oPRP) Injections Improvement In IVF Patients Based On Time-Lapse Incubator Culture for Automated Tracking and AI for Embryo Quality Assessment : A Non-Randomized Propsective Self-Controlled Interventional Study","Inclusion Criteria:\n\n* No none contraindications to IVF or PRP treatment\n* Adequate ovarian reserves and AMH level\n* Willingness to undergo two IVF cycles and oPRP treatment\n\nExclusion Criteria:\n\n* Anovulation due to menopause or perimenopause\n* Any health conditions that are contraindicated for IVF or oPRP treatment",true,"18 Years","47 Years",{"count":62,"type":22},180,[64],"NA","Patients will have ovarian PRP treatments and embryo development will be observed using time-lapse imaging and AI software.",[67,29,68,69],"Infertility","Embryo Growth Disorder","in Vitro Fertilization","RECRUITING","2025-07-08",{"date":73,"type":42},"2025-07-09",{"date":71,"type":42},{"date":76,"type":22},"2026-08-30",{"name":78,"class":49},"Generation Next Fertility"]